Cornelia Halin

Title: Cornelia Halin: Innovator in Angiogenesis Treatment

Introduction

Cornelia Halin is a prominent inventor based in Zurich, Switzerland. She has made significant contributions to the field of medical treatments, particularly in the area of angiogenesis. With a total of 3 patents to her name, her work focuses on innovative methods for treating pathological lesions.

Latest Patents

Halin's latest patents include compositions and methods for the treatment of angiogenesis in pathological lesions. These treatments target conditions such as tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. The innovative approach involves a conjugate that combines a molecule exerting a biocidal or cytotoxic effect on target cells within the lesions, along with an antibody directed against an extracellular matrix component present in these lesions. The antibodies may target fibronectin-2 (IL-2), doxorubicin, interleukin-12 (IL-12), Interferon-γ (IFN-γ), Tumor Necrosis Factor α (TNFα), or Tissue Factor protein, which may be truncated.

Career Highlights

Cornelia Halin is associated with Philogen S.p.a., a company known for its focus on biopharmaceuticals. Her work has been instrumental in advancing therapeutic options for patients suffering from various angiogenesis-related conditions.

Collaborations

Halin has collaborated with notable colleagues in her field, including Dario Neri and Luciano Zardi. Their combined expertise has contributed to the development of innovative treatments and research in angiogenesis.

Conclusion

Cornelia Halin's contributions to the field of angiogenesis treatment highlight her role as a leading inventor in medical innovation. Her patents reflect a commitment to improving patient outcomes through advanced therapeutic methods.